Trending...
- Cycurion Inc. N A S D A Q: CYCU Secures $89 Million in Contracts, New $20 Million Cyber Protection Tech Deal & Strategic Expansion into Cryptocurrency
- Phinge®, Home of Netverse® and Netaverse™ With Verified and Safer AI Announces "Test the Waters" Campaign for Potential Regulation A+ Offering
- Assent Joins AWS ISV Accelerate Program
SEATTLE, Aug. 13, 2025 ~ Seal Rock Therapeutics, Inc. has recently made a significant move in the field of Parkinson's disease research by joining The Michael J. Fox Foundation for Parkinson's Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program. This program aims to support the development of new therapies targeting LRRK2, a protein associated with Parkinson's disease.
Seal Rock Therapeutics is a clinical stage company that focuses on improving the lives of individuals living with liver, brain, or neuromuscular diseases who have limited treatment options. Their brain-penetrant LRRK2/ASK1 signaling complex (LASC) inhibitors have shown promising results in preclinical studies, demonstrating powerful neuroprotective effects.
The company's LASC inhibitors are first-in-class oral molecules that act by simultaneously blocking both LRRK2 and ASK1, another protein involved in Parkinson's disease. This dual inhibition has proven to be more effective than targeting either protein alone and has also eliminated the kidney and lung toxicity commonly seen with other LRRK2 inhibitors.
More on Washingtoner
Neil McDonnell, CEO of Seal Rock Therapeutics, expressed his excitement about joining MJFF's LITE program and being part of a consortium of academic and industry leaders who recognize the potential of LRRK2 inhibition for Parkinson's disease. He also praised MJFF for their recognition of the need for collective action and their support in pursuing this promising target.
Through their participation in the LITE initiative, Seal Rock Therapeutics hopes to gain a better understanding of their LASC inhibitors through research conducted by top labs in the field. McDonnell believes that this collaboration will not only advance their own program but also contribute to a better understanding of how ASK1 and LRRK2 play a role in Parkinson's disease.
Shalini Padmanabhan, PhD, MJFF's senior vice president and head of translational research, also expressed her enthusiasm for this partnership. She stated that the foundation remains committed to their mission of finding better treatments and a cure for Parkinson's disease. By de-risking industry investment through open-science policies and collaboration with experts, including Seal Rock Therapeutics, MJFF hopes to advance LRRK2 drug development and bring new therapies to patients faster.
The addition of Seal Rock Therapeutics to the LITE program is a significant step towards finding a cure for Parkinson's disease. With their innovative LASC inhibitors and the support of MJFF, they are poised to make a meaningful impact in the lives of those living with this debilitating disease.
Seal Rock Therapeutics is a clinical stage company that focuses on improving the lives of individuals living with liver, brain, or neuromuscular diseases who have limited treatment options. Their brain-penetrant LRRK2/ASK1 signaling complex (LASC) inhibitors have shown promising results in preclinical studies, demonstrating powerful neuroprotective effects.
The company's LASC inhibitors are first-in-class oral molecules that act by simultaneously blocking both LRRK2 and ASK1, another protein involved in Parkinson's disease. This dual inhibition has proven to be more effective than targeting either protein alone and has also eliminated the kidney and lung toxicity commonly seen with other LRRK2 inhibitors.
More on Washingtoner
- Spokane: Downtown Arson Suspect in Custody
- Spokane: Construction Project Will Impact W. Maxwell Starting Monday
- Seized Bougie Estate Court-Ordered Auction Set for August 23 in Chattanooga
- Visitors to the Florida Keys Can Receive 15 Percent Off With The 90-Day Advance Purchase Rate Discount From KeysCaribbean
- Benchmark International Successfully Facilitated the Trans of Bison Gardens and an Undisclosed Buyer
Neil McDonnell, CEO of Seal Rock Therapeutics, expressed his excitement about joining MJFF's LITE program and being part of a consortium of academic and industry leaders who recognize the potential of LRRK2 inhibition for Parkinson's disease. He also praised MJFF for their recognition of the need for collective action and their support in pursuing this promising target.
Through their participation in the LITE initiative, Seal Rock Therapeutics hopes to gain a better understanding of their LASC inhibitors through research conducted by top labs in the field. McDonnell believes that this collaboration will not only advance their own program but also contribute to a better understanding of how ASK1 and LRRK2 play a role in Parkinson's disease.
Shalini Padmanabhan, PhD, MJFF's senior vice president and head of translational research, also expressed her enthusiasm for this partnership. She stated that the foundation remains committed to their mission of finding better treatments and a cure for Parkinson's disease. By de-risking industry investment through open-science policies and collaboration with experts, including Seal Rock Therapeutics, MJFF hopes to advance LRRK2 drug development and bring new therapies to patients faster.
The addition of Seal Rock Therapeutics to the LITE program is a significant step towards finding a cure for Parkinson's disease. With their innovative LASC inhibitors and the support of MJFF, they are poised to make a meaningful impact in the lives of those living with this debilitating disease.
Filed Under: Business
0 Comments
Latest on Washingtoner
- Spokane: SPD Seeking Public Assistance in Locating Missing Endangered Person
- InventHelp Inventor Develops Versatile Footwear Product (PTA-377)
- Spokane: Fire Destroys Warehouse in East Central Neighborhood
- EZSMO Launches Premium Aged Reddit Accounts and Marketing Solutions with 15-Day Ban-Free Guarantee
- Sultry Jazz Singer Kathy Sanborn Releases Steamy Romance Language
- Vancouver Community College Forms Strategic Partnership with PebblePad
- Delirious Comedy Club and House of Magic Open 2nd Location at Silver Sevens Hotel & Casino - Vegas-Quality Shows, Old Vegas Prices
- Sumptuous Mobile Detailing Expands Premium Ceramic Coating & Mobile Car Detailing Across North Atlanta
- The Data Detective's Epic Journey: How One Author Taught a Generation to Love Data
- OddsTrader Asks: What Are the Chances Your Team Makes the NFL Playoffs?
- Iterators Named Preferred Accessibility Testing Vendor by MIT
- The 2025 "Aizu Festival" in Aizu Wakamatsu City will be held September 19–21
- Unaccredited Authority: Boeing's Role In Granting Credentials It Never Held
- University Rankings Index Announces 2025 Rankings of the Top US Online Universities
- Boston Industrial Solutions Launches Citrine® CAL-685 Silicone Primer
- Heritage at South Brunswick Announces Two New Building Releases In Townhome Collection
- New Report from The Kryder Law Group Reveals Alarming Construction Fatalities and Demographic Disparities Over the Past Decade
- EMBER™, the Only Standardized System Linking Workforce Identity to Growth, Appoints Global Brand Visionary Bret Sanford-Chung to Board of Directors
- Sober.Buzz Adds Second Podcast, "Spreading the Good BUZZ" Guest List Grows, Numbers Continue Growing Globally, All While Josh and Heidi Tied the Knot
- Council Member Sandesh Sadalge Passes Resolution 41740 to Fund 'Grit of Destiny: City of Tacoma'